Literature DB >> 18040268

Normal human primary CD4+ T lymphocytes synthesize and release functional osteoprotegerin in vitro.

Arpita Chakravarti1, Andrée-Anne Marceau, Louis Flamand, Patrice E Poubelle.   

Abstract

Osteoprotegerin (OPG) acts as a decoy receptor for receptor activator of nuclear factor-kappaB ligand (RANKL) and TNF-related apoptosis-inducing ligand (TRAIL). OPG regulates bone remodeling and the immune response. The primary objective was to decipher, among human peripheral blood mononuclear leukocytes (PBML) that produce OPG, the subset(s) responsible for this synthesis and its regulation. To this end, normal human PBML and CD4-, 8-, 19-, 14-enriched subpopulations were studied in vitro for OPG synthesis. PBML were subjected to adherence and immunomagnetic separation, and OPG expression was analyzed by PCR, northern and western blotting, and ELISA. The antiapoptotic effects of OPG were studied on TRAIL-stimulated RPMI 8226 myeloma cells. OPG was time-dependently produced by primary CD4+ T lymphocytes exclusively. OPG secretion was upregulated by anti-CD3 antibody stimulation or incubation with interleukin (IL)-4, IL-1beta, TNF-alpha, GM-CSF, and vitamin D(3). In contrast, IL-10 inhibited the basal and IL-4-induced production of OPG by T cells. Conditioned media from activated T lymphocytes decreased TRAIL-induced apoptosis of RPMI 8226 cells. This effect was reversed by addition of RANKL to the T-cell conditioned media. As human immunodeficiency virus-1 (HIV-1) targets CD4+ T cells, we evaluated the effects of recombinant HIV-1 gp120 proteins on OPG synthesis. The gp120 from three different HIV-1 strains significantly reduced the basal output of OPG from T cells. Furthermore, all four protease inhibitors (PIs) used in highly active antiretroviral therapy decreased OPG synthesis by human blood T cells, nelfinavir being the most efficient PI. The simultaneous presence of an HIV-1 gp120 and a PI abrogated the basal output of OPG. In conclusion, these results highlight a new role for T lymphocytes involved in pathologies. Activated CD4+ T cells could, through OPG release, have a paracrine effect on adjacent cells and contribute to reduce the local process of bone remodeling and cellular apoptosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18040268     DOI: 10.1038/labinvest.3700701

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  20 in total

1.  Porphyromonas gingivalis induces RANKL in T-cells.

Authors:  Georgios N Belibasakis; Durga Reddi; Nagihan Bostanci
Journal:  Inflammation       Date:  2011-04       Impact factor: 4.092

2.  T-cell receptor activator of nuclear factor-κB ligand/osteoprotegerin imbalance is associated with HIV-induced bone loss in patients with higher CD4+ T-cell counts.

Authors:  Kehmia Titanji; Aswani Vunnava; Antonina Foster; Anandi N Sheth; Jeffrey L Lennox; Andrea Knezevic; Neeta Shenvi; Kirk A Easley; Ighovwerha Ofotokun; M Neale Weitzmann
Journal:  AIDS       Date:  2018-04-24       Impact factor: 4.177

Review 3.  HIV and bone metabolism.

Authors:  Ighovwerha Ofotokun; M Neale Weitzmann
Journal:  Discov Med       Date:  2011-05       Impact factor: 2.970

4.  Deciphering how HIV-1 weakens and cracks the bone.

Authors:  Ighovwerha Ofotokun
Journal:  Proc Natl Acad Sci U S A       Date:  2018-03-01       Impact factor: 11.205

5.  Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.

Authors:  Todd T Brown; Carlee Moser; Judith S Currier; Heather J Ribaudo; Jennifer Rothenberg; Theodoros Kelesidis; Otto Yang; Michael P Dubé; Robert L Murphy; James H Stein; Grace A McComsey
Journal:  J Infect Dis       Date:  2015-05-05       Impact factor: 5.226

Review 6.  HIV-1 infection and antiretroviral therapies: risk factors for osteoporosis and bone fracture.

Authors:  Ighovwerha Ofotokun; M Neale Weitzmann
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2010-12       Impact factor: 3.243

7.  Breast cancer cells and bone marrow mesenchymal stromal cells: a regulated modulation of the breast tumor in the context of immune response.

Authors:  Mehdi Najar; Hussein Fayyad-Kazan; Wissam H Faour; Bassam Badran; Fabrice Journe; Laurence Lagneaux
Journal:  Inflamm Res       Date:  2016-10-25       Impact factor: 4.575

8.  Receptor activator of nuclear factor-κB ligand (RANKL) and its relationship to coronary atherosclerosis in HIV patients.

Authors:  Janice J Hwang; Jeffrey Wei; Suhny Abbara; Steven K Grinspoon; Janet Lo
Journal:  J Acquir Immune Defic Syndr       Date:  2012-11-01       Impact factor: 3.731

9.  Body composition, soluble markers of inflammation, and bone mineral density in antiretroviral therapy-naive HIV-1-infected individuals.

Authors:  Todd T Brown; Yun Chen; Judith S Currier; Heather J Ribaudo; Jennifer Rothenberg; Michael P Dubé; Robert Murphy; James H Stein; Grace A McComsey
Journal:  J Acquir Immune Defic Syndr       Date:  2013-07-01       Impact factor: 3.731

10.  Overexpression of osteoprotegerin promotes preosteoblast differentiation to mature osteoblasts.

Authors:  Hongyou Yu; Paul de Vos; Yijin Ren
Journal:  Angle Orthod       Date:  2011-01       Impact factor: 2.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.